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Of 384 Salmonella isolates collected from 1997 to 2000 in
a university hospital in Taiwan, six ceftriaxone-resistant isolates
of Salmonella enterica serovar Typhimurium were found in two
patients in 2000. The resistance determinants were on conjuga-
tive plasmids that encoded a CMY-2-like cephalosporinase.
During the study period, the proportion of CMY-2–like enzyme
producers among Escherichia coli increased rapidly from 0.2%
in early 1999 to >4.0% in late 2000. Klebsiella pneumoniae iso-
lates producing a CMY-2–like -lactamase did not emerge until
2000. The presence of blaCMY-containing plasmids with an iden-
tical restriction pattern from Salmonella, E. coli, and K. pneumo-
niae isolates was found, which suggests interspecies spread
and horizontal transfer of the resistance determinant. Various
nosocomial and community-acquired infections were associat-
ed with the CMY-2-like enzyme producers. Our study suggests
that the spread of plasmid-mediated CMY-2-like β-lactamases is
an emerging threat to hospitalized patients and the public in
Taiwan. 
B
ecause of increasing rates of antimicrobial resistance in
salmonellae worldwide (1-4), extended-spectrum
cephalosporins, especially ceftriaxone, are frequently used to
treat invasive salmonellosis. Since the early 1990s, ceftriaxone-
resistant salmonellae have been noted in many countries,
including France, Argentina, Algeria, Tunisia, Turkey, Spain,
Latvia, the United States, and Hungary (5-17), with resistance
conferred by various class A extended-spectrum β-lactamases
or class C cephalosporinases (18). These β-lactamases in sal-
monellae are usually encoded on transmissible plasmids (5-
11,13-17), which could be acquired from other multidrug-
resistant Enterobacteriaceae, such as Klebsiella pneumoniae or
Escherichia coli (10,19).
Although the prevalence of multidrug-resistant salmonellae
is a major public health concern, ceftriaxone-resistant salmonel-
lae have not yet been reported in Taiwan (4,20,21). We conduct-
ed a retrospective survey of clinical Salmonella isolates collect-
ed over a 4-year period in a teaching hospital to investigate
whether ceftriaxone-resistant salmonellae have emerged in
Taiwan. Two ceftriaxone-resistant strains producing a CMY-
2–like class C cephalosporinase were found. We also established
a connection between the appearance of the resistant strains and
the rapid spread of the blaCMY-2–like gene in this area.
Materials and Methods
Bacterial Isolates and Patients
From January 1997 to December 2000, a total of 384
Salmonella isolates from 324 patients were collected at the
National Cheng Kung University Hospital, a tertiary-care refer-
ral center with 900 beds in southern Taiwan. According to the
criteria of the National Committee for Clinical Laboratory
Standards (NCCLS) for the disk diffusion method, we selected
for further investigation the isolates that exhibited resistance or
intermediate resistance to cefpodoxime, ceftazidime, aztreon-
am, cefotaxime, ceftriaxone, cefoperazone, or cefixime (22).
For comparison, 5,520 E. coli isolates and 3,680 K. pneumoni-
ae isolates collected during the same period were included. Of
these isolates, 1,210 nonrepetitive E. coli isolates collected
from January to September 1999 were investigated previously
(23). The 1997 and 1998 isolates were randomly collected and
the 1999 and 2000 isolates were consecutively collected.
Salmonella isolates were serotyped according to the Kauffman
and White scheme (24) by using somatic and flagellar antigens
(Becton Dickinson Microbiology, Cockeysville, MD). 
We reviewed the medical records of patients infected with
or colonized by the organisms being studied. Patients who pro-
vided samples positive for the organisms collected from any
body site but who had no related signs or symptoms of infec-
tions were considered colonized. Nosocomial acquisition of
infections in the teaching hospital was defined according to the
1988 definitions from the Centers for Disease Control (25).
Patients transferred from other hospitals or nursing homes with
infections occurring <48 h after admission were considered to
have acquired the infections at the other locations.
Hospitalization histories for the previous locations were
recorded for outpatients and for inpatients who were colonized
by the studied organisms and who provided samples within 48
h after admission. 
Susceptibility Testing
The susceptibilities of isolates to antimicrobial agents
were determined by using the agar dilution or disk diffusion
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Children’s Hospital, Taoyuan, Taiwanmethod according to the NCCLS guidelines (22,26). The
antimicrobial agents used for the agar dilution test included
amoxicillin, clavulanic acid, ceftriaxone, cefoxitin, cef-
tazidime, cefotaxime, and imipenem. Sources of antimicrobial
agents used in this study are described elsewhere (23).
Breakpoints used for susceptibility meet NCCLS criteria; the
ceftazidime, cefotaxime, and ceftriaxone breakpoint was 8
µg/mL (26).
Isoelectric Focusing
Crude β-lactamase extracts were prepared by using sonica-
tion (27) as described previously (23). We performed isoelec-
tric focusing by the method of Matthew et al. (28) with an LKB
Multiphor apparatus on prepared PAGplate gels (pH 3.5 to 9.5;
Amersham Pharmacia Biotech, Hong Kong, China). Enzyme
activities of β-lactamases were detected by overlaying the gel
with 0.5 mM nitrocefin in 0.1 M phosphate buffer, pH 7.0. We
used TEM-1, TEM-10, SHV-1, SHV-5, CMY-1, CTX-M-3, and
CMY-2 β-lactamases as standards (18,23). 
Conjugation Experiments and Plasmid Analysis
Conjugation experiments were performed by the liquid
mating-out assay as described (29) with streptomycin-resistant
E. coli C600 as the recipient (30). Transconjugants were select-
ed on tryptic soy agar plates supplemented by 500 µg of strep-
tomycin and 10 µg of ceftazidime per milliliter. Plasmids from
transconjugants were extracted by using a rapid alkaline lysis
procedure (31). We analyzed restriction fragment length poly-
morphism of transferred plasmids using agarose gel elec-
trophoresis of plasmid DNA samples treated with the restric-
tion endonuclease EcoRI (Roche Molecular Biochemicals,
Mannheim, Germany). The restricted plasmid DNA samples
were then transferred to a nylon membrane (Amersham
Pharmacia Biotech) and subjected to Southern hybridization.
The plasmid sizes of transconjugants were estimated by adding
restriction fragments.
Molecular Techniques
Plasmid preparations from clinical isolates and their
transconjugants were used as templates in polymerase chain
reaction (PCR) assays. Genes related to blaTEM, blaSHV, blaCMY-1,
blaCMY-2, and blaCTX-M-3 were amplified with the oligonucleotide
primers as described (23). Primers 5´-ATAAAATTCTTGAA-
GACGAAA-3´ and 5´-GACAGTTACCAATGCTTAATCA-3´,
corresponding to nucleotides -5 to 15 and 1,074 to 1,053,
respectively, of the blaTEM-1 structural gene (32), were used to
amplify the entire sequences of blaTEM-related genes. Primers
AmpC-1C (5´-CTGCTGCTGACAGCCTCTTT-3´) and
AmpC-1B (5´-TTTTCAAGAATGCGCCAGGC-3´) (23),
which correspond to nucleotides 28-47 and 1,136-1,117,
respectively, of the blaCMY-2 structural gene (33), were used to
amplify an internal fragment of approximately 95% of blaCMY-
2-related genes. Both strands of the amplified products were
sequenced on an ABI PRISM 310 automated sequencer
(Applied Biosystems, Foster City, CA). Colony hybridization
and Southern hybridization were performed as described
(34,35) with DNA probes prepared from the PCR-generated
amplicons. The probes were labeled with [α
-32P]dCTP
(Amersham Pharmacia Biotech) by using the random priming
technique with a commercial kit (GibcoBRL Life
Technologies, Gaithersburg, MD).
The genetic relatedness of ceftriaxone-resistant
Salmonella isolates was investigated by ribotyping by using the
method described by Popovic et al. (36). The chromosomal
DNA was extracted and digested overnight with 10 U of SphI
and PstI or EcoRI (Roche Molecular Biochemicals) (36,37). A
cDNA probe was prepared by reverse transcription of 16S plus
23S rRNA (Roche Molecular Biochemicals) and was labeled
with [a
-32P]dCTP. DNA molecular marker II (Roche Molecular
Biochemicals) and 1-kb molecular marker (Promega Corp.,
Madison, WI) were used as size standards.
Results
Emergence of Salmonella Isolates 
Producing CMY-2-Like Enzymes
Six of 384 Salmonella isolates displayed intermediate
resistance to ceftriaxone by the disk diffusion method. The iso-
lates were recovered from stool samples of two patients who
had community-acquired enteric infections in August and
November 2000, respectively, which were identified as S.
enterica serovar Typhimurium. One isolate from each patient
(isolates ST275/00 and ST595/00) was investigated further.
Both isolates demonstrated reduced susceptibilities to cef-
tazidime (MIC 64 µg/mL), cefotaxime (MIC 16 µg/mL), ceftri-
axone (MIC 32 µg/mL), cefoxitin (MIC 128 µg/mL), and
amoxicillin-clavulanic acid (MIC 64 µg/mL) and were suscep-
tible to imipenem (MIC 0.25 µg/mL). Both isolates were sus-
ceptible to ciprofloxacin and trimethoprim-sulfamethoxazole
by the disk diffusion method. Isolate ST275/00 was resistant to
chloramphenicol, while isolate ST595/00 was susceptible.
Isoelectric focusing showed that both isolates expressed two β-
lactamases focusing at pIs 5.4 and 9.0, suggesting that they pro-
duced a TEM-1–like enzyme and an AmpC-like β-lactamase.
Both isolates yielded an approximately 1.1-kb DNA fragment
in PCR with primers for blaCMY-2–like genes, and the amplified
sequences obtained by nucleotide sequencing were identical to
the homologous region of blaCMY-2, which encodes a class C
extended-spectrum cephalosporinase (33). A narrow-spectrum
β-lactamase gene, blaTEM-1 (18) was also detected by PCR and
nucleotide sequencing in both isolates. The two ceftriaxone-
resistant Salmonella isolates had different ribotypes, suggest-
ing that they are of different clones (Figure 1).
Prevalence of the blaCMY-2–Like Gene 
in E. coli and K. pneumoniae Isolates
We found that 659 of 5,520 E. coli and 409 of 3,680 K.
pneumoniae isolates showed resistance to at least one extend-
ed-spectrum cephalosporin by the disk diffusion test. These
isolates were subjected to colony hybridization and PCR
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and 4 K. pneumoniae isolates from 2 patients gave a strong sig-
nal in colony hybridization with the blaCMY-2 probe and gave
positive results in PCR with the primers for blaCMY-2. Sequence
analysis indicated that the sequences of all amplicons were
identical to the homologous region of blaCMY-2. The prevalence
rates of CMY-2-like enzyme producers in E. coli increased
from 0% in 1997 and 1998 to >4% in late 2000 (Figure 2).
Among the patients with E. coli isolates, the incidence of
patients with blaCMY-positive isolates increased from 0.0% in
1997 and 1998 to 3.6% in late 2000 (Figure 2).
The sources of E. coli isolates harboring a blaCMY-2–like
gene and the infections associated with these isolates are sum-
marized in the Table. The isolates and patients are distributed
according to the likely locations of infection or colonization. Of
the 97 blaCMY-positive E. coli isolates, 8 isolates were likely
acquired in the community by eight patients. Six of these
patients had never been hospitalized, and two had been hospi-
talized 10 months or 2 years before isolation. K. pneumoniae
isolates producing the CMY-2-like enzyme were associated
with nosocomial bloodstream infections in two patients.
Notably, E. coli (EC811/00) and K. pneumoniae (KP218/00)
isolates were recovered from the blood sample of a single
patient. 
Conjugation Experiments and Plasmid Analysis
One isolate from each patient was subjected to conjugation
experiments and plasmid analysis. The blaCMY-positive plasmids
were successfully transferred to E. coli C600 from 2 Salmonella
isolates, 40 of 48 E. coli isolates, and 2 K. pneumoniae isolates.
All  E. coli transconjugants and their plasmid donors showed
decreased susceptibilities to ceftazidime (MIC >32 µg/mL),
cefotaxime (MIC >16 µg/mL), ceftriaxone (MIC >32 µg/mL),
and cefoxitin (MIC >64 µg/mL). The sizes of the transferred
plasmids ranged from approximately 65 kb to >100 kb. 
Restricted by EcoRI, the plasmids from transconjugants of
E. coli isolates showed 19 restriction patterns, designated TP1-
TP19 (Figures 3A and 3C). Patterns TP17 (lane 17) and TP19
(lane 19), the most common patterns, were shown by 6 and 17
transferred plasmids, respectively. Of the 17 isolates with a
TP19 plasmid, 3 were acquired from nursing homes and 5 from
the community. Of the six isolates with a TP17 plasmid, two
could have been acquired from the community. We considered
that the remaining isolates with a TP17 or TP19 plasmid were
acquired in the university hospital. Each of the remaining 17
patterns was shown by a single transferred plasmid. The TP19
pattern is the only restriction pattern displayed by transconju-
gants of all three studied bacterial species: Salmonella (lane
21), K. pneumoniae (lane 22), and E. coli (lane 24). Notably, K.
pneumoniae isolate KP218/00 and E. coli isolate EC811/00,
from the same patient, both had a TP19-type plasmid. The plas-
mids from transconjugants of Salmonella isolate ST275/00
(lane 20) and another K. pneumoniae isolate KP1905/00 (lane
21) showed two distinct restriction patterns. The presence of
the blaCMY-2-like gene on plasmids was confirmed by Southern
hybridization with the blaCMY-2 probe (Figures 3B and 3D).
Discussion
Emergence of ceftriaxone-resistant salmonellae has
become a great public health concern worldwide (5-17). In
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Figure 1. Ribotyping profiles of the two ceftriaxone-resistant Salmonella
isolates generated by digestion of chromosomal DNAwith SphI and PstI
(lanes 1 and 2) or EcoRI (lanes 3 and 4). Lanes 1 and 3, isolate
ST275/00; lanes 2 and 4, isolate ST595/00; lane M, 1-kb DNA ladder
(Promega Corp., Madison, WI).
Figure 2. Prevalence rates of the blaCMY-2–like gene among clinical iso-
lates of Escherichia coli () and percentage of the new cases infected
with or colonized by the E. coli isolates producing the CMY-2–like
enzyme among patients with E. coli isolates (), 1999 and 2000.
Numbers over bars denote the numbers of isolates with a CMY-2–like
ß-lactamase or the numbers of patients with these isolates.Taiwan, no ceftriaxone-resistant isolates were detected from
several surveys, which included isolates collected from 1989 to
1998 (4,20,21). One of the surveys was conducted in National
Cheng Kung University Hospital (4), and one survey conduct-
ed in 1998 included isolates from 22 hospitals (21). In the pres-
ent study, Salmonella isolates resistant to extended-spectrum β-
lactams were not detected until August 2000.  Thus, the appear-
ance of ceftriaxone-resistant Salmonella strains is likely a
recent event.
Production of a CMY-2–like β-lactamase was responsible
for resistance to extended-spectrum β-lactams in the
Salmonella strains we isolated. The spread of blaCMY-2 in salmo-
nellae recently was reported to be an emerging problem in the
United States (14,15). In Taiwan, the blaCMY-2–like gene was first
detected in E. coli isolates collected in 1999 in the university
hospital (23). The fact that the blaCMY-2–like gene was found in
few isolates from patients with community-acquired infections
suggested that the genetic determinant had spread in the com-
munity environment (23). The appearance of the blaCMY-2–like
gene in the Salmonella isolates supports our previous specula-
tion on the spread of the genetic determinant in the community
environment. Moreover, the discovery of patients who might
have acquired E. coli isolates with the CMY-2-like enzyme
from nursing homes and in the community (Table) suggests
widespread distribution of the blaCMY-2–like gene in southern
Taiwan. 
Conjugation experiments and plasmid analysis demon-
strated the prevalence of conjugative resistance plasmids TP17
and TP19 among E. coli isolates. These E. coli isolates were
recovered from patients hospitalized in the teaching hospital,
transferred from nursing homes, or without recent hospitaliza-
tion histories (Figure 3). Furthermore, the TP19 plasmid was
found in a Salmonella strain and a K. pneumoniae strain, which
suggests the interspecies spread of the blaCMY-2–like gene among
different health-care settings and the community in Taiwan.
The dissemination of the resistance determinant is probably
partly because of horizontal transfer of endemic resistance
plasmids.
All  K. pneumoniae isolates producing the CMY-2-like
enzyme were acquired by patients hospitalized in the universi-
ty hospital. Producers of the CMY-2–like enzyme in K. pneu-
moniae were not found until 2000 and, even then, remained
very rare (38). Isolate KP218/00 (lane 22, Figure 3C) and E.
coli isolate EC811/00 (lane 24, Figure 3C) were obtained from
the same patient, and both isolates had a TP19 plasmid, sug-
gesting interspecies spread of a resistance plasmid. Thus, the
acquisition of the blaCMY-2 gene by K. pneumoniae in this hospi-
tal was likely also a recent event, which occurred after spread
of the resistance determinant.
Enterobacteriaceae with plasmid-encoded class C
cephalosporinases are typically resistant to cephamycins,
extended-spectrum cephalosporins, and monobactams (19). No
standard methods exist to detect class C cephalosporinases
(39). Failure to detect and report CMY-2–like enzyme produc-
ers, and a lack of infection control measures against such
organisms might be partially responsible for the rapid spread of
the blaCMY-2–like gene in E. coli and the increased cases of infec-
tions caused by such organisms in our hospital (Table). With
the discovery of Salmonella isolates producing the CMY-2-like
enzyme in Taiwan, our study suggests that the cephalospori-
nase could become an emerging threat, not only to hospitalized
patients, but also to public health. Constant and consistent sur-
veillance is needed to prevent its further spread.
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Table. Likely sources of Escherichia coli isolates producing a CMY-2–like β-lactamase and types of infection associated with the isolates 
No. (%) of isolates or patients
a 
Specimen or infection  NCKU
b  Nursing home  Community  Total 
Specimen         
   Blood  12 (14.4)  2 (33.3)  0 (0)  14 (14.4) 
   Urine  23 (27.7)  1 (16.7)  6 (75.0)  30 (30.9) 
   Sputum  17 (20.5)  2 (33.3)  1 (12.5)  20 (20.6) 
   Wound  23 (27.7)  0 (0)  0 (0)  23 (23.7) 
   Body fluid  2 (2.4)  1 (16.7)  0 (0)  3 (3.1) 
   Miscellaneous  6 (7.2)  0 (0)  1 (12.5)  7 (7.2) 
 Total isolate no.  83 (100)  6 (100)  8 (100)  97 (100) 
Infection         
   Bacteremia  6 (16.7)  1 (25.0)  0 (0)  7 (14.6) 
   Urinary tract infection  8 (22.2)  0 (0)  3 (37.5)  11 (22.9) 
   Pneumonia  1 (2.8)  1 (25.0)  0 (0)  2 (4.2) 
   Wound infection  9 (25.0)  0 (0)  0 (0)  9 (18.8) 
   Colonization  12 (33.3)  2 (50.0)  5 (62.5)  19 (39.6) 
 Total patient no.  36 (100)  4 (100)  8 (100)  48 (100) 
aIsolates and patients are distributed by the likely locations of infection or colonization. 
bNCKU, National Cheng Kung University Hospital. References
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